PGP and ovarian cancer: In summary, we demonstrate that the covalent microtubule stabilizer, taccalonolide AF, is less susceptible to Pgp-mediated resistance than paclitaxel and has a higher degree of cellular persistence after drug washout, providing an advantage in taxane-resistant ovarian cancer models both in vitro and in vivo.